Eplerenone for the Treatment of Central Serous Chorioretinopathy

Trial Profile

Eplerenone for the Treatment of Central Serous Chorioretinopathy

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Central serous chorioretinopathy
  • Focus Therapeutic Use
  • Acronyms ECSelsior
  • Most Recent Events

    • 09 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 19 Feb 2015 Planned End Date changed from 1 Oct 2014 to 1 May 2015 as per ClinicalTrials.gov record.
    • 19 Feb 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Mar 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top